Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. Self-administration by pre-filled syringe (PFS) can offer patients clinical benefits of a drug, with increased convenience. To assess efficacy, safety and usability of secukinumab administration via PFS in subjects with moderate-to-severe plaque psoriasis. Subjects in this phase 3 trial were randomized 1 : 1 : 1 to secukinumab 300 or 150 mg or matching placebo. Results to week 12 are presented here. Each treatment was delivered using a PFS once weekly to week 4, and again at week 8. Co-primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 (≥ 75% reduction in Psoriasis Area and Severity Index) and IGA mod 2011 (2011 modified Investigator's Global Assessment) 0/1 response rates. Secondary endpoints included PFS usability, determined by observer rating of successful, hazard-free self-injection and subject rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ). Co-primary endpoints were met, with demonstration of superiority for each secukinumab dose vs. placebo at week 12 (PASI 75: 75·9%, 69·5% and 0% for secukinumab 300 mg, 150 mg and placebo; IGA mod 2011 0/1: 69·0%, 52·5% and 0%, respectively; P < 0·0001 for all comparisons vs. placebo). PFS usability was high: 100% of subjects successfully self-administered treatment at week 1, and subjects reported high SIAQ-assessed acceptability of the PFS throughout the trial. No new/unexpected safety signals were observed. Secukinumab administration by PFS was effective, with an acceptable safety profile and high usability. The PFS provides a reliable, convenient form of secukinumab administration in subjects with moderate-to-severe plaque psoriasis.
Secukinumab , a fully human anti - interleukin-17A monoclonal antibody , demonstrated efficacy and safety in moderate - to - severe plaque psoriasis when administered via subcutaneous injection . Self - administration by pre - filled syringe ( PFS ) can offer patients clinical benefits of a drug , with increased convenience . To assess efficacy , safety and usability of secukinumab administration via PFS in subjects with moderate - to - severe plaque psoriasis . Subjects in this phase 3 trial were randomized 1 : 1 : 1 to secukinumab 300 or 150 mg or matching placebo . Results to week 12 are presented here . Each treatment was delivered using a PFS once weekly to week 4 , and again at week 8 . Co - primary endpoints were secukinumab superiority over placebo for week 12 PASI 75 ( ≥ 75 % reduction in Psoriasis Area and Severity Index ) and IGA mod 2011 ( 2011 modified Investigator 's Global Assessment ) 0/1 response rates . Secondary endpoints included PFS usability , determined by observer rating of successful , hazard - free self - injection and subject rating of acceptability by the Self - Injection Assessment Questionnaire ( SIAQ ) . Co - primary endpoints were met , with demonstration of superiority for each secukinumab dose vs. placebo at week 12 ( PASI 75 : 75·9 % , 69·5 % and 0 % for secukinumab 300 mg , 150 mg and placebo ; IGA mod 2011 0/1 : 69·0 % , 52·5 % and 0 % , respectively ; P < 0·0001 for all comparisons vs. placebo ) . PFS usability was high : 100 % of subjects successfully self - administered treatment at week 1 , and subjects reported high SIAQ - assessed acceptability of the PFS throughout the trial . No new / unexpected safety signals were observed . Secukinumab administration by PFS was effective , with an acceptable safety profile and high usability . The PFS provides a reliable , convenient form of secukinumab administration in subjects with moderate - to - severe plaque psoriasis .
Which molecule is targeted by a monoclonal antibody Secukinumab?
Which molecule is targeted by a monoclonal antibody Secukinumab ?
interleukin-17A
interleukin-17A